HF2768 Summary

• Expands pharmacist practice of pharmacy to include intramuscular and subcutaneous drug administration for treating mental illnesses either upon prescriber order with post-administration notification or under a protocol or collaborative practice agreement with authorized practitioners.

• Removes the previous limitation restricting intramuscular and subcutaneous drug administration to only alcohol or opioid dependence treatment, broadening the scope to mental illness treatment.

• Authorizes pharmacists to place drug monitoring devices according to a prescription, protocol, or collaborative practice agreement.

• Requires pharmacists administering drugs for mental illness under a protocol or collaborative practice agreement to document changes in the patient's medical record or report to a responsible practitioner.